Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Grifols, S.A.NASDAQ: GRFS

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities broadly unchanged from a year ago

Deferred tax liabilities stood at €926M at the end of Q2 FY2026, up 0.4% from a year earlier. Over 3 fiscal years it compounded at -4.3% a year.

Context

  • Deferred tax liabilities amounted to 4.6% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred tax liabilities keeps rising in the next quarterly balance sheet after a +0.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€926M— QoQ
Last fiscal yearDec 2025
€906.61M-10.4% YoY
Year agoJun 2025
€922.27M+0.4% since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year-10.4%——
3-year CAGR-4.3%——
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

EUR · from the balance sheet

Latest · FY2025
906.61M EUR
Year-over-year change
-10.4%

Deferred Tax Liabilities vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.4% is the 4th highest of 6, against a peer median of +2.2%.
  • Deferred tax liabilities amounts to 4.6% of total assets for GRFS, versus a peer median of 1.2%.
GRFS Competitors
Deferred Tax Liabilities for GRFS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BDXBecton, Dickinson and CompanySep 2026$2.2B USD—-3.5%4.3%
BIOBio-Rad Laboratories, Inc.Jun 2026$982.2M USD+2.2%-15.7%9.6%
GRFSGrifols, S.A.Jun 2026€926M EUR+0.4%-4.3%4.6%
QDELQuidelOrtho CorporationMar 2026$87.3M USD+11.6%-25.0%1.6%
HAEHaemonetics CorporationJun 2026$38.69M USD-35.0%+1.7%1.6%
TECHBio-Techne CorporationSep 2026$23.51M USD+108.5%+7.8%0.9%
ABTAbbott LaboratoriesJun 2026$0 USD—+2.0%0.0%
ADMAADMA Biologics, Inc.Jun 2026$0 USD——0.0%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$0 USD-100.0%—0.0%
Peer median (excluding GRFS) —+2.2%-0.9%1.2%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents655.49M549.21M529.58M979.78M824.65M
Short-term Investments2.03B31.03M116.47M21.18M0
Net Receivables434.14M774.2M692.86M1.08B844.64M
Inventory2.26B3.24B3.48B3.56B3.29B
Other Current Assets131.63M80.88M1.31B78.58M100.96M
Total Current Assets5.51B4.69B6.13B5.73B5.07B
Property, Plant & Equipment (Net)3.34B4.28B4.19B4.31B4.05B
Goodwill6.23B7.01B6.8B7.4B6.83B
Intangible Assets1B2.95B1.21B2.93B2.73B
Long-term Investments2.27B1.99B451.9M528.97M592.75M
Tax Assets0174.92M0341.67M461.8M
Other Non-current Assets882.61M124.19M2.21B167.72M15.99M
Total Non-current Assets13.72B16.54B14.86B15.68B14.68B
Total Assets19.23B21.23B20.99B21.41B19.75B
Account Payables628.99M787.96M822.95M852.31M840.64M
Short-term Debt2.35B578.92M916.51M523.13M385.84M
Tax Payables015.69M084.99M0
Deferred Revenue037.83M070.87M76.97M
Other Current Liabilities119.44M381.59M108.6M81.95M459.8M
Total Current Liabilities3.47B2.02B2.33B2.16B2.02B
Long-term Debt6.94B8.15B8.99B8.42B7.39B
Deferred Tax Liabilities01.03B01.01B906.61M
Deferred Revenue (Non-current)015.12M013.94M0
Other Non-current Liabilities675.34M1.12B1.16B170.46M854.64M
Total Non-current Liabilities8.44B11.23B11.15B10.64B10.12B
Total Liabilities11.92B13.25B13.48B12.8B12.13B
Common Stock119.6M119.6M119.6M119.6M119.95M
Retained Earnings248M079.36M156.92M0
Accumulated OCI4.41B4.78B4.41B4.83B4.37B
Other Stockholders Equity00000
Minority Interest1.79B2.33B2.15B2.72B2.33B
Total Equity7.32B7.98B7.51B8.61B7.6B
Total Debt10.17B9.75B11.02B10.09B8.74B
Net Debt9.51B9.2B10.49B9.11B7.92B

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.